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Striatal medium-sized spiny neurons (MSNs), com-
posed of striatonigral and striatopallidal neurons,
are derived from the lateral ganglionic eminence
(LGE). We find that the transcription factor Sp9 is ex-
pressed in LGE progenitors that generate nearly all
striatal MSNs and that Sp9 expression is maintained
in postmitotic striatopallidal MSNs. Sp9-null mice
lose most striatopallidal MSNs because of decreased
proliferation of striatopallidal MSN progenitors and
increased Bax-dependent apoptosis, whereas the
development of striatonigral neurons is largely unaf-
fected. ChIP qPCR provides evidence that Ascl1
directly binds the Sp9 promoter. RNA-seq and
in situ hybridization reveal that Sp9 promotes expres-
sion of Adora2a, P2ry1, Gpr6, and Grik3 in the LGE
and striatum. Thus, Sp9 is crucial for the generation,
differentiation, and survival of striatopallidal MSNs.INTRODUCTION
The striatum (caudate nucleus and putamen) is the largest
component of the basal ganglia. The majority of striatal neurons
(90%–95%) are DARPP-32-expressing (+), GABAergic, medium-
sized spiny neurons (MSNs). Two major subtypes of MSNs send
outputs to other components of the basal ganglia: striatonigral
(direct pathway) and striatopallidal (indirect pathway). Striatonig-
ral MSNs express the dopamine D1 receptor (Drd1) and neuro-
peptide Tac1 (known as substance P), whereas striatopallidal
MSNs express the dopamine D2 receptor (Drd2) and neuropep-
tide enkephalin (Enk) (Gerfen, 1992; Gerfen et al., 1990; Gerfen
and Surmeier, 2011; Kawaguchi et al., 1990). About 5%–10%
of neurons in the striatum are aspiny interneurons. They areCell R
This is an open access article undcholine acetyltransferase (ChAT)+, parvalbumin (PV)+, somato-
statin (SST)+ and calretinin (CR)+ (Kawaguchi et al., 1995).
Interneurons in the mouse striatum are known to mainly origi-
nate from the medial ganglionic eminence (MGE) (Marin et al.,
2000; Xu et al., 2008). Recent studies provide evidence that hu-
man and monkey striatal interneurons are also derived from the
MGE (Wang et al., 2014). The lateral ganglionic eminence (LGE),
the primordium of the striatum, contains two distinct compart-
ments: a dorsal part, which is the source of most interneurons
in the olfactory bulb (Stenman et al., 2003; Waclaw et al., 2006;
Yun et al., 2001), and a ventral part, which generates striatal
MSNs (Anderson et al., 1997; Deacon et al., 1994; Olsson
et al., 1995, 1998; Stenman et al., 2003).
Translational profiles of striatonigral and striatopallidal MSNs
have been defined using the fluorescent activated cell sorting
(FACS) and translating ribosome affinity purification (TRAP) ap-
proaches. These studies identified more than 200 striatonigrally
enriched genes and more than 100 striatopallidally enriched
genes (Ena et al., 2013; Heiman et al., 2008; Lobo et al., 2006).
Some transcriptional factors (TFs) that control striatal MSN
development are beginning to be identified. Dlx1 and Dlx2 are
required for generating late-born MSNs (Anderson et al., 1997),
whereas Dlx6 controls striatal regional molecular properties
(Wang et al., 2011). Bcl11b (also known as Ctip2) is critical for
the differentiation of all MSNs (Arlotta et al., 2008). Ebf1 is essen-
tial for the differentiation of striatonigral MSNs (Lobo et al., 2006,
2008). The LIM homeobox gene Isl1 is required for the specifica-
tion of striatonigral cell identity and the correct development of
the striatonigral pathway (Ehrman et al., 2013; Lu et al., 2014).
Thus, we know some of the TFs involved inmaking the striatonig-
ral MSNs, but little is known about the molecular mechanisms
controlling the development of striatopallidal MSNs.
Here we investigated the role of the Sp9 zinc finger TF in the
development of MSNs. Sp9 is widely expressed in the ganglionic
eminences (GEs) and in all striatopallidal MSNs. We generated a
Sp9-Cre knockinmouse and found that Sp9+ progenitors give riseeports 16, 1431–1444, August 2, 2016 ª 2016 The Author(s). 1431
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to most GABAergic neurons in the telencephalon, including
cortical and olfactory bulb interneurons, striatal MSNs, and stria-
tal interneurons. In postmitotic MSNs, Sp9 is specifically ex-
pressed in all striatopallidal neurons but not in striatonigral neu-
rons. We also generated Sp9LacZ/LacZ-null mutant mice and
observed a 97% reduction of striatopallidal MSNs but saw little
change in striatonigral MSNs. Bromodeoxyuridine (BrdU) pulse-
labeling and BrdU birth-dating experiments indicated that the
neurogenesis ability of LGE progenitors, especially striatopallidal
MSNprogenitors,was compromised.Moreover, loss ofSp9 func-
tion resulted in a lack of striatopallidal neuron differentiation and
Bax-dependent apoptosis in the striatum during postnatal life.
Conditional inactivation of Sp9 using Drd2-Cre transgenic mice
further revealed that the function of Sp9 in regulating striatopalli-
dal MSN survival, at least in part, was cell-autonomous. Chro-
matin immunoprecipitation (ChIP) qPCR experiments showed
that Ascl1 was upstream of Sp9 in the LGE and directly bound
to its promoter. Finally, RNA sequencing (RNA-seq) and RNA
in situ hybridization indicate that the prosurvival effect of Sp9 in
striatopallidal MSNs may be through promoting the expression
of three G protein-coupled receptors (GPCRs), including adeno-
sine A2a receptor (Adora2a), purinergic receptor P2Y, G pro-
tein-coupled 1 (P2ry1) andGpr6, and glutamate ionotropic recep-
tor kainate type subunit 3 (Grik3). Taken together, our studies
uncover a crucial role for Sp9 in the generation, differentiation,
and survival of striatopallidal MSNs.
RESULTS
Sp9 Is Widely Expressed in the LGE, MGE, and Caudal
Ganglionic Eminence
To systematically study the expression and function of the TF
Sp9 in the telencephalon, we generated Sp9 polyclonal anti-
bodies and several Sp9 mutant alleles. Based on the
‘‘knockout-first’’ strategy (Skarnes et al., 2011; Testa et al.,
2004), we generated a Sp9 knockout-first null allele that, in
turn, produced a Sp9-LacZ null allele (Sp9LacZ/+) and a Sp9
floxed allele (Sp9Flox/+) following exposure to germline recombi-
nases Zp3-Cre (de Vries et al., 2000) and ACTB-Flpe (Rodrı´guez
et al., 2000), respectively (Figures S1A–S1D).
Sp9-LacZ expression was detected in the GEs at embryonic
day (E) 10.5 (Figures 1A–1D). Immunocytochemistry of Sp9
and Sp9-LacZ (b-galactosidase [b-gal]) and in situ Sp9 RNA hy-
bridization demonstrated that Sp9 RNA and Sp9 protein were
widely expressed in the subventricular zone (SVZ) and mantle
zone of the LGE, MGE, and CGE (caudal ganglionic eminence)
at E13.5 (Figures 1E–1H). A subset of Sp9+ cells in the SVZ of
GEs expressed the proneural protein Ascl1 and cell proliferation
marker Ki67 (Figures 1I–1K). This suggests that, although Sp9 is
not detectable in radial glia cells (primary stem/progenitor cells)
in the ventricular zone (VZ), it is expressed in a subpopulation of
dividing progenitors in the SVZ and postmitotic neurons in the
mantle zone. The GEs generate neocortical interneurons,
including in humans (Hansen et al., 2013; Ma et al., 2013). We
observed that most migrating cortical interneurons expressed
Sp9 at embryonic developmental stages (Figures 1E–1H). Sp9
protein and Sp9 RNA were not detected in Sp9LacZ/LacZ mutant
mice (data not shown).1432 Cell Reports 16, 1431–1444, August 2, 2016Sp9+ Progenitors Generate Most Neocortical and
Striatal GABAergic Neurons
To genetically identify the progenies of Sp9+ progenitors, we
generated Sp9-Cre knockin mice (Figure S1). Fate mapping at
postnatal day (P) 30 using Sp9-Cre; Rosa-YFP mice showed
that Sp9+ progenitors generated >96% of cortical interneurons
(including PV+, SST+, CR+, NPY (neuropeptide Y)+, and VIP
(vasoactive intestinal polypeptide)+ subtypes; Figures S2A–
S2M) and virtually all striatal interneurons (PV+, SST+, CR+, and
ChAT+; Figures S2N–S2Q and S2S). Foxp1 is expressed by all
postmitotic MSNs and is excluded from other striatal cell types
(Arlotta et al., 2008; Tamura et al., 2004). All Foxp1+ cells were
GFP+ (Figures S2R and S2S), demonstrating that Sp9-Cre is
active during the development of both striatopallidal and striato-
nigral MSNs.
In the olfactory bulb (OB), the identities of GFP+ cells were diffi-
cult to determine because of the high density of interneurons
(Figure S2A). However, from the broad expression of GFP, we
speculated that Sp9+ progenitors also give rise to most (perhaps
all) OB interneurons.We confirmed all of these results usingSp9-
Cre; Ai14 mouse lines (data not shown).
Sp9 Is Specifically Expressed in Drd2+ Striatopallidal
MSNs
Using Drd2-EGFP transgenic mice (Gong et al., 2003), we
determined the specificity of Sp9’s striatal expression (Fig-
ure S3). Sp9 was strongly expressed in the prenatal striatum;
its expression continued into adulthood, albeit at a lower level
(Figures S3A–S3L). Virtually all GFP+ cells (Drd2+ striatopallidal
MSNs) in the Drd2-EGFP transgenic mouse striatum ex-
pressed Sp9 at E16.5, P0, P5, P17, and P35 (Figures S3A–
S3L and S3O). In contrast, only about 7% of striatonigral
MSNs in Drd1-EGFP mice expressed Sp9 at P5, and Sp9
was not detectable in Drd1-GFP+ MSNs at P35 (Figure S3M).
This result shows that Sp9 is expressed in both progenitors of
striatopallidal and striatonigral MSNs, but, in postmitotic
MSNs, Sp9 expression becomes restricted to Drd2+ striato-
pallidal MSNs. Next we assessed whether Sp9 regulated the
development of MSNs.
Most Striatopallidal MSNs Are Lost in Sp9LacZ/LacZ
Mutant Mice
To investigate the function of Sp9 in the development of the stria-
tum, we first analyzed Sp9LacZ/LacZ mutant mice. Although
Sp9LacZ/+ mice (referred to as controls) developed normally
and were fertile, Sp9LacZ/LacZ mutant mice failed to thrive and
developed general weakness from P7 onward (Figure 2A). These
mice started to die at P14, and none survived beyond P22. The
brain sizes andweights of theSp9mutants were grossly reduced
compared with controls at P20 (Figures 2B and 2C).
The most prominent phenotype in the Sp9 mutant telenceph-
alon was atrophy of the striatum; the volume of mutant striatum
was reduced to 54% of controls at P9 (Figures 2D and 2E).
Compared with Sp9LacZ/+; Drd2-EGFP mice (Figures 2F–2J),
we observed loss 57% of Foxp1+ cells and 97% of Foxp1+/
Drd2-GFP+ cells in the striatum of Sp9LacZ/LacZ; Drd2-EGFP
mice at P9 (Figures 2K–2O, 2X, and 2Y). The remaining
Foxp1+/Drd2-GFP+ cells were not evenly distributed in the
Figure 1. Sp9 Is Widely Expressed in the LGE, MGE, and CGE
(A–D) Sp9 expression by whole-mount b-gal staining on E9.5–E12.5 embryos of Sp9LacZ/+ mice.
(E–H) Sp9 protein, Sp9 mRNA, and Sp9-LacZ were widely expressed in the SVZ and mantle zone of E13.5 mouse LGE, MGE, and CGE.
(I–K) Sp9/Ascl1 and Sp9/Ki67 double-immunostained E13.5 mouse brain section showing Sp9+/Ascl1+ and Sp9+/Ki67+ cells in the SVZ of the LGE.
Scale bars, 200 mm in (H) for (E)–(H) and 20 mm in (K) for (I)–(K).mutant striatum. In the dorsal medial striatum, Foxp1+/Drd2-
GFP+ cells were barely detectable (Figure 2M). In contrast,
most remaining Foxp1+/Drd2-GFP+ cells were located in the
lateral striatum (Figure 2M), a population of MSNs that are gener-
ated at early developmental stages (Anderson et al., 1997). Drd2
in situ hybridization confirmed the loss of the cell type with this
molecular signature (Figures 2P and 2T). Furthermore, the mu-
tants showed severe loss of Enk+ cells, further evidence for a
defect in striatopallidal MSNs (Figures 2R and 2V). A small pop-
ulation of Drd2-GFP+ cells remained in the dorsal striatum of Sp9
mutants; however, these Drd2-GFP+ cells expressed ChAT and
thus were an interneuron subtype (Figures 2Q and 2U; Durieux
et al., 2009).Striatal MSNs are roughly equally divided into striatopallidal
and striatonigral neurons. Although Drd1+ and Drd1-GFP+ stria-
tonigral neurons were apparently not affected (Figures 2S and
2W), the observation of loss 57% of striatal Foxp1+ cells in
Sp9LacZ/LacZmutant striatum (Figure 2X) suggests that striatonig-
ral MSNs are slightly affected.
The Sp9 Mutant LGE SVZ Has Reduced Proliferation
To test whether Sp9 regulates cell proliferation in the LGE, we
performed 30-min BrdU pulse labeling at E13.5 and E15.5 (Fig-
ures 3A–3H). At E13.5, the number of BrdU+ cells in the
Sp9LacZ/LacZ mutants was reduced in the SVZ but not the VZ (Fig-
ure 3M). At E15.5, we observed a reduction in SVZ BrdU+Cell Reports 16, 1431–1444, August 2, 2016 1433
Figure 2. Striatopallidal MSNs Are Lost in Postnatal Sp9LacZ/LacZ Mutants
(A) Sp9+/+, Sp9LacZ/+, and Sp9LacZ/LacZ littermates were taken at P20 to compare their sizes.
(B) P20 images of Sp9LacZ/+ and Sp9LacZ/LacZ brains.
(C) Brains were weighed at P20. The weight of Sp9LacZ/LacZ was significantly reduced compared with Sp9LacZ/+ controls (Student’s t test, ***p < 0.001, n = 6,
mean ± SEM).
(D and E) Telencephalon coronal section of Sp9LacZ/+ control and Sp9LacZ/LacZ mutant counterstained with DAPI at P9. Note the reduction of striatal (Str) size in
Sp9LacZ/LacZ mutants compared with Sp9LacZ/+ controls. Scale bar, 1 mm.
(F–J) Foxp1/GFP double-immunostained striatal sections from Drd2-EGFP; Sp9LacZ/+ P9 mice.
(K–O) Foxp1/GFP double-immunostained striatal sections from Drd2-EGFP; Sp9LacZ/LacZ mutant mice at P9 showed severe reduction of GFP+ striatopallidal
MSNs. Note that almost all GFP+ striatopallidal MSNs were eliminated in the dorsal medial striatum.
(P and T) Severe reduction of Drd2 RNA in Sp9LacZ/LacZ mouse striatum at P9, shown by in situ hybridization.
(Q and U) In the dorsal striatum of Drd2-EGFP; Sp9LacZ/+ control mice (Q), less than 3% of Drd2-GFP+ cells expressed ChAT, whereas, in the dorsal striatum of
Drd2-EGFP; Sp9LacZ/LacZ mutant mice (U), most of the remaining Drd2-GFP+ cells express ChAT (>67%), suggesting they are ChAT+ interneurons rather than
striatopallidal MSNs.
(R and V) Severe reduction of Enk+ cells in Sp9LacZ/LacZ mice compared with Sp9LacZ/+ mice at P9, shown by immunostaining.
(legend continued on next page)
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progenitor cells and in SVZ Foxp1+ postmitotic MSNs (Figures
3E–3H and 3N).
Next we performed a BrdU birth-dating analysis. An injection
of BrdU was given at E12.5, and the number of BrdU+ and
BrdU+/Foxp1+ cells were counted in the striatum of P0 in
Sp9LacZ/LacZ and wild-type littermate controls (Figures 3I–3L).
The mutants had reduced BrdU+ cells (996 ± 73 cells versus
526 ± 62.5 cells per striatal section, p = 0.0081) and BrdU+/
Foxp1+ cells (911 ± 79.7 cells versus 465 ± 52.7 cells per striatal
section, p = 0.0095; controls versus mutants) (Figures 3O and
3P). The percentage of BrdU+ and BrdU+/Foxp1+ cells was
reduced in a similar ratio (47.2% versus 49%). Thus, loss of
Sp9 function results in a loss of cycling progenitors (BrdU pulse
label data) in the LGE SVZ, which results in loss of striatal MSNs
(BrdU birth dating data).
Sp9 Specifically Regulates the Production of
Striatopallidal MSNs
We took advantage of b-gal expression from the Sp9LacZ mutant
allele to follow Sp9+ MSNs in the striatum of Sp9mutant mice. At
P0, we found that both b-gal+ (3638 ± 302.1 versus 1223 ±
108.6, p = 0.0016) and b-gal+/Foxp1+ (2,866 ± 202.8 versus
219 ± 10.8, p = 0.0058) cells were greatly reduced in the
Sp9LacZ/LacZ mutant striatum compared with Sp9LacZ/+ control
striatum (Figures S4A–S4F). Because Sp9 is expressed in all
striatopallidal MSNs and only in a few striatonigral MSNs, this
provides evidence that loss of Sp9 preferentially blocks produc-
tion of striatopallidal MSNs.
To further assess the production of striatal MSNs at E16.5, we
performed in situ RNA hybridization using ten striatal MSN
markers. We used five markers for striatopallidal MSNs (Drd2,
Penk,Gpr6, Adora2a, and Ptprm) and five markers for striatonig-
ral MSNs (Drd1, Tac1, Ebf1, Pdyn, and Chrm4) for striatonigral
MSNs (Gerfen et al., 1990; Heiman et al., 2008; Lobo et al.,
2006). All markers were detectable in Sp9LacZ/+ controls,
although Gpr6 had low expression at this time point (Figures
4A–4J). In contrast, in Sp9LacZ/LacZ mutant SVZ and striatum,
striatopallidal MSN markers were either almost undetectable
(Gpr6 and Adora2a) or greatly downregulated (Drd2, Penk, and
Ptprm) (Figures 4F’–4J’). Our qRT-PCR analysis revealed similar
results (Figure 4Q). On the other hand, striatonigral marker
expression was modestly affected (Figure 4A’–4E’). These re-
sults further support the evidence from the BrdU birth dating
and Sp9-b-gal quantification data: large population of mature
striatopallidal MSNs are not produced in the absence of Sp9.
Next we compared GFP expression from theDrd2-EGFP allele
in control versus Sp9 mutant E16.5 and P0 striatum (Sp9LacZ/+
versus Sp9LacZ/LacZ). The mutant had very few Foxp1+/Drd2-
GFP+ MSN cells in the SVZ and striatum (Figures 4K–4P and
4R). Taken together, these results indicate that Sp9 specifically
promotes the production of striatopallidal MSNs in the striatum.(S andW) Drd1/GFP double-immunostained striatal sections from P9 controls (Drd
Drd1 and Drd1-GFP was not obviously reduced in Sp9 mutant striatum compare
(X and Y) Approximately 57% of Foxp1+ and 97% Foxp1+/Drd2-GFP+ cells were
with the control (Drd2-EGFP; Sp9LacZ/+) (Student’s t test, ***p < 0.001, n = 3, me
Scale bars, 200 mm in (W) for (F)–(H), (K)–(M), (P), (R)–(T), (V), and (W) and 50 mmLoss of Sp9 Induces Bax-Dependent Apoptosis in the
Postnatal Striatum
We next analyzed cell death in Sp9LacZ/LacZ mutant postnatal
striatum, as marked by cleaved Caspase-3 expression. The
number of Caspase-3+ cells in the striatum of control mice
increased from P0, reached amaximum at P3, and then declined
(Figures 5A and 5C). The mutant had a robust increase in the
number of Caspase-3+ cells in the striatum at all postnatal stages
analyzed (P0, P3, P5, and P7) (Figures 5B and 5C). Becausemost
mature striatopallidal MSNswere not generated (becausewe did
not observe Caspase-3+ cells express Drd2-GFP and because
we did not observe a severe reduction of striatonigral MSNs),
we inferred that most of the dying cells in Sp9 mutant striatum
were immature striatopallidal MSNs.
To determine whether Sp9LacZ/LacZ striatopallidal MSNs
apoptosis was Bcl-2-associated X protein (Bax)-dependent,
we generated Sp9LacZ/LacZ; Bax/ double mutants. We found
that striatal cell death was nearly absent in the Sp9LacZ/LacZ;
Bax/ double mutants at P3 (data not shown). We analyzed
the numbers of Foxp1+ cells in the striatum of Sp9LacZ/+;
Bax/+, Sp9LacZ/LacZ; Bax/+ and Sp9LacZ/LacZ; Bax/ mice at
P15 (Figures S5A–S5I and S5P) and found that the number
of Foxp1+ cells in Sp9LacZ/LacZ; Bax/ striatum was signifi-
cantly larger than that in Sp9LacZ/LacZ; Bax/+ striatum (Fig-
ure S5P). Perhaps because this genetic manipulation did not
rescue Sp9-mediated cell proliferation in the LGE SVZ, the
number of Foxp1+ cells in Sp9LacZ/LacZ; Bax/ striatum was
still smaller than that in Sp9LacZ/+; Bax/+ striatum (controls)
(Figure S5P).
We noted that the ‘‘rescued’’ Foxp1+ cells in Sp9LacZ/LacZ;
Bax/ mutant failed to fully mature into striatopallidal MSNs
as they did not express Enk, Drd2, and Adora2a at P15 (Figures
S5J–S5O; data not shown), suggesting that, in addition to pro-
moting LGE proliferation and survival, Sp9 is essential for the dif-
ferentiation and maturation of striatopallidal neurons.
Sp9 in Striatopallidal MSNs Is Required for Their
Survival
All striatopallidal MSNs in the striatum express Sp9 (Figure S3).
To directly investigate the requirement of Sp9 in postmitotic
striatopallidal MSNs, we utilized a conditional knockout strategy.
We generated Sp9 conditional mouse mutants by breeding male
Drd2-Cre; Sp9Flox/+micewith femaleSp9Flox/Floxmice (Figure S1)
with or without the Rosa-YFP Cre reporter allele. The Drd2-Cre
transgene expresses Cre specifically in immature and mature
striatopallidal MSNs (Gong et al., 2007). The offspring of this
cross, including Drd2-Cre; Sp9Flox/Flox conditional mutants,
developed normally and were fertile.
We quantified the number of Foxp1+ and Foxp1+/GFP+ cells
in the striatum of Drd2-Cre; Sp9Flox/Flox; Rosa-YFP mice and
Drd2-Cre; Sp9Flox/Flox; Rosa-YFP triple-transgenic mice at P301-EGFP; Sp9LacZ/+) andmutants (Drd1-EGFP; Sp9LacZ/LacZ). The expression of
d with controls.
reduced in the P9 striatum of the mutant (Drd2-EGFP; Sp9LacZ/LacZ) compared
an ± SEM).
in (U) for (I), (J), (N), (O), (Q), and (U).
Cell Reports 16, 1431–1444, August 2, 2016 1435
Figure 3. Sp9 Mutants: Reduction of Proliferation in the LGE SVZ and Reduction of MSN Production in the Striatum
(A–H) Immunostaining of BrdU and Foxp1 of LGE sections at E13.5 and E15.5 30 min after a BrdU pulse.
(M andN) Quantification showing that Sp9LacZ/LacZmutants had reducedBrdU+ and Foxp1+cells in the SVZ but not in the VZ (Student’s t test, *p < 0.05, **p < 0.01,
***p < 0.001, n = 3, mean ± SEM).
(I–L) Immunostaining of BrdU and Foxp1 of striatal sections at P0 after a BrdU injection at E12.5.
(O and P) Quantification showing that Sp9mutants had reduced BrdU+ and BrdU+/Foxp1+cells in the striatum (Student’s t test, **p < 0.01, n = 3, mean ± SEM).
Scale bar, 50 mm in (L) for (A)–(H) and (I)–(L).(Figures 5D–5F). Themutants had decreased numbers of Foxp1+
and Foxp1+/GFP+ cells (Figure 5F). Next we analyzed cell death
in the striatum of thesemice. Similar to Sp9 constitutive mutants,
the striatum of Sp9 conditional mutants had increased numbers
of Caspase-3+ cells at P0, P3, and P5 (Figures 5G–5I). Thus, the
loss of Drd2+ striatopallidal MSNs in Sp9 conditional mutants
was due to cell programmed death, demonstrating that Sp9
expression in postmitotic striatopallidal MSNs is necessary for
their survival.1436 Cell Reports 16, 1431–1444, August 2, 2016Loss of Striatopallidal MSNsResults in Hyperlocomotion
Activation of the striatonigral (direct) pathway promotes locomo-
tion, whereas activation of the striatopallidal (indirect) pathway
inhibits locomotion (Durieux et al., 2009, 2012; Kravitz et al.,
2010). Therefore, the loss of striatopallidal MSNs observed in
the Drd2-Cre; Sp9Flox/Flox conditional mutant mice could influ-
ence locomotive behaviors. To test this, we examined the loco-
motive activity of 2-month-old Drd2-Cre; Sp9Flox/Flox, Drd2-Cre;
Sp9Flox/+ (control) and Sp9Flox/+ (control) mice in an open field.
Figure 4. Most Mature Striatopallidal MSNs Are not Generated in Sp9 Mutants
(A–E’) In situ RNA hybridization of striatonigral MSN markers on E16.5 brain sections showing that the development of striatonigral MSN was less affected.
(F–J’) RNA expression of striatopallidal markers was significantly reduced. Note the complete loss of Adora2a RNA in the Sp9mutant LGE SVZ and mantle zone
(striatum) except for a few cells in the lateral striatum (H’).
(K–P) Most Drd2-EGFP+ cells were lost in the SVZ and striatum at E16.5 and P0.
(Q and R) Validation of striatopallidal MSN loss in the E16.5 LGE by qPCR (Q) and quantification of Foxp1+, Foxp1+/Drd2-GFP+, and Foxp1+ but Drd2-GFP
(negative) cells in the LGE SVZ at E16.5 (R) (Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3, mean ± SEM.
Scale bars, 100 mm in (P) for (A)–(K), (M), (N), and (P) and 50 mm in (O) for (L) and (O).
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Figure 5. Programmed Cell Death Eliminates Striatopallidal MSNs in Postnatal Sp9 Constitutive and Conditional Mutants
(A and B) Significant increase in expression of cleaved Caspase-3 in Sp9 mutant striatum compared with controls at P3.
(C) Temporal profile of numbers of Caspase-3+ cells in postnatal striatum in Sp9mutant and control mice (one-way ANOVA followed by Tukey-Kramer post hoc
test, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3, mean ± SEM).
(D–F) Foxp1/GFP double-immunostaining revealed a significant decrease in numbers of Foxp1+ and Foxp1+/GFP+ cells in the striatum of Drd2-Cre; Sp9Flox/Flox;
Rosa-YFP conditional mutants compared with Drd2-Cre; Sp9Flox/+; Rosa-YFP (controls) at P30 (Student’s t test, **p < 0.01, ***p < 0.001, n = 3, mean ± SEM).
Scale bar, 50 mm.
(G–I) Caspase-3+ cells in controls and Sp9 conditional mutants at P3 showing a significant increase in the numbers of Caspase-3+ cells in the striatum of Sp9
conditional mutants compared with controls at P0, P3, and P5 (one-way ANOVA followed Tukey-Kramer post hoc test, **p < 0.01, ***p < 0.001, n = 3, mean ± SEM).
(J and K) In the open field test, adult Drd2-Cre; Sp9Flox/Flox mice exhibited increased locomotor activity compared with Sp9Flox/+ or Drd2-Cre; Sp9Flox/+ littermate
controls (J, measured by the total distance), but they exhibited similar anxiety related behavior (K, measured by the center distance/total distance ratio) (one-way
ANOVA followed Tukey-Kramer post hoc test, *p < 0.05, mean ± SEM).
(L) In the rotarod test, adult Drd2-Cre; Sp9Flox/Flox mice and littermate control mice displayed similar motor coordination and learning ability in the latency to fall
during 3 training days (days 1, 2, 3) and one trial day (day 4).
Scale bar, 100 mm in (H) for (A), (B), (G), and (H).
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Compared with controls, Drd2-Cre; Sp9Flox/Flox mice exhibited a
significant increase in locomotion based on the total distance
traveled (Figure 5J). However, on the basis of the ratio of the cen-
ter to the total distance in the open field test, we did not observe
any significant difference in anxiety-related behaviors (Fig-
ure 5K). In addition, Drd2-Cre; Sp9Flox/Flox mice showed normal
performance in a rotarod test (Figure 5L), indicating normal mo-
tor coordination and motor learning. Overall, these experiments
indicate that loss of striatopallidal MSNs inDrd2-Cre; Sp9Flox/Flox
mice resulted in hyperlocomotion but no measurable change in
anxiety or motor coordination/learning.
Ascl1 Directly Binds Sp9’s Promoter and Enhances Its
Expression In Vivo
Previous studies have shown that the proneural factor Ascl1 is
required for the production of striatal Drd2+ MSNs at E18.5 (Ca-
sarosa et al., 1999). We confirmed this result using in situ RNA
hybridization. Compared with Ascl1GFP/+ control mice, the
expression level of Drd2 in P0 Ascl1GFP/GFP mutant mice was
severely reduced (Figures S6E and S6F), whereas the expres-
sion of Drd1 was less affected (Figures S6G and S6H). We
also observed that the expression of Sp9 (both protein and
RNA) was reduced in the ventral LGE SVZ of Ascl1GFP/GFP mu-
tants at E14.5 and E16.5 (Figures 6A–6D; Figures S6A–S6D),
suggesting that Ascl1 positively regulates Sp9 expression.
This is consistent with previous reports (Long et al., 2009a,
2009b).
Ascl1 promotes cell differentiation and proliferation in GEs
(Castro et al., 2011). Thus, it is possible that Ascl1 controls
striatopallidal MSN progenitor proliferation in the LGE SVZ
through Sp9. To test this hypothesis, we informatically stud-
ied the putative promoter and enhancers near the Sp9 locus.
We found the consensus Ascl1 binding motif (E-box sites,
CAGCTG or CACCTG) in the putative promoter and in two
enhancers (E953 and E245) (Castro et al., 2011; Pacary
et al., 2011; Figure 6E). To determine whether Ascl1 physi-
cally associates with these regulation regions, we carried
out ChIP qPCR using an Ascl1 rabbit polyclonal antibody
and chromatin prepared from E13.5 LGE of wild-type mice.
The Rnd3 E1 enhancer (Rnd3 E1) was used as a positive
control because previous studies demonstrated that Ascl1
promotes Rnd3 expression in the embryonic brain by a direct
regulation of Rnd3 E1 (Pacary et al., 2011). We found that the
Rnd3 E1, Sp9 putative promoter, E953, and E245 were all
enriched in the immunoprecipitated genomic DNA over input
(Figure 6F).
We performed a dual-luciferase transcription activation
assay using the P19 embryonal carcinoma cell line. Ascl1 acti-
vated transcription from Sp9’s putative promoter and, to a
lesser extent, from Sp9 E245 (Figure 6G), whereas it did not
activate Sp9 E953 (Figure 6G). Finally, we found that the
Ascl1 binding motif (CAGCTG) contributed to the regulation
of the Sp9 promoter because deletion CAGCTG attenuated
Ascl1-mediated activation (Figure 6H). Together, these results
provide evidence that Ascl1 promotes Sp9 expression in the
LGE SVZ, at least in part, through its direct binding to the pro-
moter and, possibly, other regulatory elements within the Sp9
locus (e.g., E245).Sp9 Promotes Adora2a Expression in the Striatum
To investigate the cause of striatopallidal MSN apoptosis in
Drd2-Cre; Sp9Flox/Flox conditional knockout mice, we performed
RNA-seq analysis. We compared gene expression profiles from
the P0 littermate Sp9Flox/Flox control striatum (including SVZ) and
conditional mutant striatum of Drd2-Cre; Sp9Flox/Flox mice and
identified about 90 genes that were either significantly upregu-
lated or downregulated in Drd2-Cre; Sp9Flox/Flox mice (Table
S1) (GEO: GSE83373). Of these, we found that the expression
of three GPCRs (Adora2a, Gpr6, and P2ry1) was significantly
decreased in Sp9 conditional mutant striatum, especially
Adora2a (p = 0.0000000134, Q value = 0.00000115) (Table S2).
Two of them (Adora2a and Gpr6) are markers for striatopallidal
MSNs (Heiman et al., 2008; Lobo et al., 2006); the third one
(P2ry1) is predominately expressed in striatopallidal MSNs dur-
ing development. In addition, Grik3 expression was also greatly
reduced in Sp9 conditional mutant striatum. Becausemost stria-
topallidal MSNs have not yet died at P0, the majority of striato-
pallidal MSN-specific genes were not significantly downregu-
lated (Table S2), and none of the striatonigral MSN-specific
genes were significantly downregulated (Table S2). We postulate
that genes with an expression difference prior to cell death may
lead to apoptosis.
To validate our RNA-seq results, we performed RNA in situ hy-
bridization on E16, E18, and P4 sections with a number of these
genes (Figure 7; Figure S7). First, we confirmed the absence of
Sp9 in the mutant LGE mantle zone (striatum) at E16 (normal
expression in the SVZ is present because the Cre eliminates
Sp9 in the mantle zone). GFP+ and Cre+ cells were present in
the striatum as apoptosis had not begun (Figures S7A–S7C’).
The development of striatonigral MSNs appeared normal based
on expression of their markersDrd1 and Ebf1 (Figure S7D–S7E’).
Expression of the striatopallidal MSN markers Drd2, Penk, and
Ptprm was slightly reduced (Figures S7F, 7F’, and 7I–7J’). Strik-
ingly, Adora2a RNA striatal expression was almost undetectable
(Figures S7G and S7G’), and Gpr6 expression was severely
reduced (Figures S7H and S7H’; Table S2). Similar results were
also observed in E18 striatum (Figures 7A–7H’). In addition, we
observed that the expression of P2ry1 and Grik3 was greatly
reduced (Figures 7I–7J’), consistent with our RNA-seq data. At
P4, we began to observe the loss of Drd2+ striatopallidal
MSNs in Sp9 conditional mutant striatum (Figures S7K and
S7K’). However, based on our in situ RNA hybridization, Adora2a
RNA expression remained almost undetectable (Figures S7L and
S7L’), and Gpr6, P2ry1, and Grik3 expression was still severely
reduced in Sp9 conditional striatum (Figures S7M–S7O’). These
data indicate that Sp9 is required to drive Adora2a expression in
striatopallidal MSNs. Furthermore, the Sp9 conditional mutants
had reduced expression of two other GPCRs, Gpr6 and P2ry1,
and the glutamate ionotropic receptor Grik3 in striatopallidal
MSNs.
Adora2a, among its many functions, participates in protecting
cells from neuronal death after brain insults (Chen et al., 2007;
Rivera-Oliver and Dı´az-Rı´os, 2014). We propose that the
apoptotic cell death of striatopallidal MSNs in the Sp9 condi-
tional mutant is likely in part a consequence of the loss of
Adora2a expression along with attenuated expression of Gpr6,
P2ry1, and Grik3.Cell Reports 16, 1431–1444, August 2, 2016 1439
Figure 6. Ascl1 Directly Regulates the Sp9 Expression in the LGE
(A–D) Sp9 expression in the LGE was reduced in Ascl1GFP/GFP mutant mice compared with Ascl1GFP/+ control mice at E14.5. Scale bar, 200 mm.
(E) Evolutionarily conserved noncoding elements in the Sp9 locus (putative promoter and enhancers E953 and E245) contain the consensus Ascl1-binding motif
(E-box sites, CAGCTG or CACCTG).
(F) Ascl1 ChIP-qPCR demonstrated Ascl1 binding in chromatin from wild-type E13.5 LGE to the Sp9 putative promoter, E953, and E245. Rnd3 E1 is a positive
control.
(G) Ascl1 activated transcription from the Sp9 putative promoter and E245 in a dual-luciferase assay within P19 cells (Student’s t test, *p < 0.05, n = 3 individuals,
mean ± SEM).
(H) Deletion of the Ascl1 binding motif reduced activation of the Sp9 putative promoter by Ascl1 (Student’s t test, *p < 0.05, n = 3 individuals, mean ± SEM).DISCUSSION
Here we find that Sp9 has several critical roles in striatal MSN
development. Sp9+ LGE progenitors generate most MSNs, and
Sp9 expression is maintained in postmitotic striatopallidal
MSNs but not striatonigral MSNs. In the absence of Sp9, striatal
development was disrupted for three main reasons: LGE SVZ
cell proliferation was reduced, striatopallidal MSN differentiation
and maturation were arrested, and Bax-dependent apoptosis of
these neurons occurred. The latter two processes largely did not
affect striatonigral neurons. We suggest that Ascl1 drives Sp9
expression in the SVZ through binding and activation of the1440 Cell Reports 16, 1431–1444, August 2, 2016Sp9 promoter. Finally, striatopallidal MSN survival is mediated
in part through Sp9 driving the expression of several GPCRs,
especially Adora2a.
Sp9 Specifically Promotes Striatopallidal MSN
Progenitor Cell Division in the LGE SVZ
Sp9 expression is detected in the SVZ but not the VZ (primary
neural stem/progenitors) of the GEs. Sp9 is co-expressed with
the progenitor cell markers Ascl1 and Ki67 particularly at the
VZ-SVZ boundary (also known as SVZ1) (Petryniak et al., 2007;
Figures 1I–1K). The reduced numbers of S-phase cells labeled
by BrdU pulse at E13.5 and E15.5 in the constitutive null mutant
Figure 7. Sp9 Promotes the Expression of GPCRs in Striatopallidal MSNs
(A and A’) Sp9 RNA expression in the striatum was greatly reduced in Drd2-Cre; Sp9Flox/Flox conditional mutants compared with Sp9Flox/Flox controls at E18,
whereas its expression in the SVZ appeared normal.
(B–C’) Drd1 and Tac1 RNA expression appeared normal.
(D–G’) Striatal expression of Drd2, Penk, and Ptprmwas slightly reduced, whereas expression of Adora2awas nearly undetectable except in the lateral striatum.
(H–J’) Expression of Gpr6, P2ry1, and Grik3 was greatly reduced in the striatum.
Scale bar, 200 mm in (J’) for (A)–(J’).mice indicate that Sp9 promotes proliferation of the progenitors.
This reduced proliferation leads to reduced LGE neurogenesis,
as revealed by our BrdU birth-dating analysis, based on a signif-
icant reduction of BrdU+ and BrdU+/Foxp1+ cells in the Sp9
mutant striatum at P0 (Figures 3I–3L, 3O, and 3P). Thus,
decreased progenitor proliferation contributes to reduced
numbers ofMSNs in themutantmice. Although Sp9+ progenitors
in the LGE SVZ give rise to all striatal MSNs, Sp9 expression is
restricted to striatopallidal MSNs in the striatum because only
a few of striatonigral MSNs express Sp9. Using the Sp9-LacZ
mutant allele, we found that there was a significant reduction
of b-gal+ cells in P0 Sp9 mutant striatum compared with
Sp9LacZ/+ controls (Figure S4). This strongly suggests that the
function of Sp9 in the LGESVZ ismainly promoting striatopallidal
MSN progenitor cell proliferation.Regulation of Sp9 Expression in the LGE by Ascl1
Ascl1 is a basic helix-loop-helix proneural TF that is expressed
in the VZ and SVZ of the GEs. Ascl1 expression has been
shown to promote both cell proliferation (Castro et al., 2011)
and cell-cycle exit (Castro et al., 2006; Farah et al., 2000;
Nakada et al., 2004). In this study, we showed that Ascl1 is
co-expressed with Sp9 in the SVZ of the LGE (Figures 1I and
1J). In Ascl1 mutant mice, the expression of Sp9 is reduced
(Figures S6A–S6D; Figures 6A–6D). These data indicate that
Sp9 is genetically downstream of Ascl1. We also found that
loss of striatopallidal MSNs was more severe than loss of stria-
tonigral MSNs in Ascl1 mutant striatum (Figures S6E–S6H).
Thus, Ascl1 mutants phenocopy Sp9 mutants; both have
reduced LGE cell proliferation and Drd2 striatal expression
(Casarosa et al., 1999; Castro et al., 2011). Ascl1 ChIP-chipCell Reports 16, 1431–1444, August 2, 2016 1441
(ChIP with promoter microarrays) analysis revealed that Ascl1
activates a large number of positive cell-cycle regulators (Cas-
tro et al., 2011). We thus hypothesized that Ascl1 regulates the
development of striatopallidal MSNs in part through controlling
Sp9 expression, which specifically promotes striatopallidal
MSN progenitor division. Indeed, our ChIP qPCR experiments
supported this idea by showing that Ascl1 directly binds to
Sp9’s promoter.
Sp9 Controls the Survival of Striatopallidal MSNs Likely
via Positively Regulating GPCR Expression
Sp9 expression and function starts from LGE progenitors and
then becomes restricted to differentiating striatopallidal MSNs.
Consistent with this expression pattern, reduction of cycling
progenitors was observed in the Sp9 constitutive mutant LGE
SVZ, and a reduction of markers of striatopallidal MSNs was
observed in the LGE mantle zone (striatum) of Sp9 constitutive
and conditional mutants. The Sp9 constitutivemutant may result
in the premature cell-cycle exit of striatopallidal MSN. These
neurons have a differentiation defect (fail to express markers
of striatopallidal MSNs) and undergo Bax-dependent apoptosis
largely in the early postnatal period. Indeed, we never observed
striatal Caspase-3+ cells that expressed Drd2-GFP. Conditional
inactivation of Sp9 in striatopallidal MSNs using Drd2-Cre trans-
genic mice largely phenocopied the striatal defects of Sp9
constitutive mutants, showing that elimination of Sp9 beginning
at E13.5 in striatal postmitotic neurons leads to the failure of
striatopallidal MSN differentiation followed by their apoptotic
elimination.
Previous studies have shown that Ntrk2 (known as TrkB), a
receptor for brain-derived neurotrophic factor (BDNF), is
required for the development of striatum and survival of stria-
topallidal MSNs (Baydyuk et al., 2011; Li et al., 2012). How-
ever, we did not find altered RNA expression of Ntrk2 in the
embryonic striatum of Sp9 mutants (Figures S7C and S7D).
This suggests that programmed cell death occurring in the
Sp9 mutant striatum is not due to the lack of Ntrk2. By
contrast, we observed that the expression of GPCRs in
striatopallidal MSNs was downregulated in the absence of
Sp9 at E16.5, E18, and P4 striatum. These GPCRs are
Adora2a, Gpr6, and P2ry1. Adora2a and Gpr6 are only ex-
pressed in striatopallidal MSNs; P2ry1 is mainly expressed in
striatopallidal MSNs during development. We also noted that
the expression of Adora2a remained barely detectable in
Sp9 constitutive and conditional mutants from E16 to P4.
This demonstrated that the expression of Adora2a in striato-
pallidal MSNs was dependent on Sp9.
Adora2a mediates neuroprotection against brain injuries in
various animal models of neurological disorders. Adora2a
can either promote or protect from cell death depending on
the nature of brain injuries (Chen et al., 2007; Rivera-Oliver
and Dı´az-Rı´os, 2014). We show that Sp9 is required for
Adora2a expression in differentiating and mature striatopalli-
dal MSNs. We propose that the nearly complete loss of
Adora2a, combined with partial loss of Gpr6, P2ry1, and
Grik3 in striatopallidal MSNs during development, contrib-
uted to the striatal apoptotic cell death in Sp9 conditional
mutants.1442 Cell Reports 16, 1431–1444, August 2, 2016Loss of Striatopallidal MSNs and Human Disease
Aberrant basal ganglion circuitry leads to locomotor dysfunc-
tion in humans. Many diseases, such as Huntington’s disease
(HD) and attention deficit/hyperactivity disorder (ADHD), are
associated with abnormal striatal MSNs (Russell, 2007; Vonsat-
tel et al., 1985). A dramatic decrease in the expression of
Adora2a in the striatum is evident at a very early stage of HD
(Glass et al., 2000). The preferential loss of striatopallidal
MSNs in the early and middle phases of HD contributes to
choreiform movements (Mitchell et al., 1999; Reiner et al.,
1988). Because Drd2-Cre; Sp9Flox/Flox mutants have hyperloco-
motion, this further supports the idea that striatopallidal MSNs
promote movement inhibition (Kravitz et al., 2010). Thus,
Drd2-Cre; Sp9Flox/Flox mutants may serve as a model to study
basal ganglion disorders caused by abnormal development
and survival of striatopallidal MSNs.EXPERIMENTAL PROCEDURES
Animals
All experiments were performed in accordance with institutional guidelines.
We generated Sp9LacZ/+ mice, Sp9Flox/+, mice and Sp9-Cre knockin mice in
this study. See the Supplemental Experimental Procedures for detailed
methods. Other mouse strains used in this study were Drd2-EGFP, Drd2-
Cre, and Drd1-EGFP (Gong et al., 2003, 2007) (from Mutant Mouse Resource
Research Centers [MMRRC]), Ascl1GFP/+ knockin knockout (Kim et al., 2007;
Leung et al., 2007); and Bax-/+ (Knudson et al., 1995). We used two Cre-re-
porter mouse lines in this study: Rosa-YFP (Srinivas et al., 2001) and Ai14
(Madisen et al., 2010). All lines in this study were maintained in a mixed genetic
background of C57BL/6J, 129S6, and CD1.
RNA-Seq
The striatum (including the SVZ) from P0 Sp9Flox/Flox littermate controls and
Drd2-Cre; Sp9Flox/Flox conditional mutants were dissected (n = 3 in each
group). Total RNA was purified with a mini RNA isolation kit (ZymoGenetics).
RNA-seq was performed as recommended by the manufacturer (Illumina).
Levels of gene expression were reported in fragments per kilobase of exon
per million fragments mapped (FPKM) (Trapnell et al., 2012). A gene was
considered to be expressed when it had FPKM > 1. For a gene to be called
as differentially expressed, it required p < 0.05. Data from this experiment
were deposited in GEO: GSE83373.
ChIP and qPCR
ChIP was performed on E13.5 LGE using Ascl1 rabbit polyclonal antibody
(Cosmo Bio, SK-T01-003). Co-precipitated DNAs were purified with phenol-
chloroform and detected by qRT-PCR (Vogt et al., 2014). The Rnd3 E1 was
the positive control (Pacary et al., 2011). See the Experimental Procedures
for detailed methods.
Luciferase Assays
The DNA fragments of the E953 and E245 enhancers of the Sp9 gene
were created by PCR and subsequently cloned into the pGL4.23 firefly
luciferase vector (Promega) upstream (U) or downstream (D) of the Luc2
gene (e.g., pGL4.23-E953U or pGL4.23-E953D). The putative Sp9 pro-
moter was amplified by PCR and cloned into the pGL4.10 promoterless
firefly luciferase vector (Promega). Cells from the mouse embryonal
carcinoma cell line P19 were grown in medium MEMa (Gibco, 12571-
063) supplemented with 10% fetal bovine serum (FBS) (Gibco, 10099-
141). For the luciferase assay, P19 cell transfections were performed in
triplicate in 24-well plates by using Fugene HD transfection reagent ac-
cording to the manufacturer’s protocol (Promega, E2311). Luciferase
sparks were quantified by a microplate luminometer (Turner BioSystems,
Modulus microplate reader).
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